Skip to content

US · MLTX · BIOTECHNOLOGY

MoonLake Immunotherapeutics (MLTX) intrinsic value and stock valuation

$11.07as of 2026-11-21 · Mkt cap 1.48B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

MoonLake Immunotherapeutics DCF and intrinsic value

InvestorsCraft values MLTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MLTX’s statements →

MoonLake Immunotherapeutics Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Zug, ZG 6300 moonlaketx.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-227.32M
20202025
Free cash flow
-$-196.04M
20202025
Total equity
$304.5M+22% 5y CAGRd
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-244.83M-$-143.09M-$-54.12M-$-65.06M-$-53.58M
Net income-$-227.32M-$-118.94M-$-36.01M-$-49.97M-$-53.64M
EPSd-$-3.53M-$-1.89M-$-733.1K-$-1.7M-$-1.45M
Operating cash flow-$-196.01M-$-116.59M-$-42.78M-$-55.89M-$-35.18M
Capital expenditure-$-40K-$-520K-$-280K-$-20K-$-50K
Free cash flow-$-196.04M-$-117.11M-$-43.06M-$-55.91M-$-35.23M
Total assets$424.4M$477.9M$526.5M$76.8M$9.68M
Total debt$75.7M$2.83M$3.7M$280K$15M
Net debt-$-258.81M-$-177.6M-$-447.47M-$-39.22M$6.96M
Total equity$304.5M$453.4M$513.5M$68.8M-$-11.65M
Cash and short-term investments$394M$448M$511M$72.1M$8.04M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$2.62M$0.00$0.00$0.00$0.00
Gross profit-$-2.62M$0.00$0.00$0.00-$0.00
Research and development expenses$202.9M$112.8M$31.8M$42.1M$35.5M
Selling, general and administrative expenses$42M$30.3M$22.3M$23M$18.1M
Other expenses-$-2.62M$0.00$0.00$0.00$0.00
Operating expenses$242.2M$143.1M$54.1M$65.1M$53.6M
Cost and expenses$244.8M$143.1M$54.1M$65.1M$53.6M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$7.25M$0.00$0.00$0.00$0.00
Depreciation and amortization$2.62M$1.38M$370K$160K$0.00
Ebitda-$-219.85M-$-119.58M-$-43.61M-$-64.3M-$-53.63M
Operating income-$-244.83M-$-143.09M-$-54.12M-$-65.06M-$-53.58M
Total other income/expenses, net$15.1M$22.1M$10.1M$590K-$-60K
Income before tax-$-229.71M-$-120.96M-$-43.98M-$-64.47M-$-53.64M
Income tax expense$610K$280K$90K$40K$0.00
Net income-$-227.32M-$-118.94M-$-36.01M-$-49.97M-$-53.64M
Weighted average shares outstanding$64.5M$62.9M$49.1M$29.4M$36.9M
Weighted average diluted shares outstanding$64.5M$62.9M$49.1M$29.4M$36.9M
Balance sheet
20252024202320222021
Cash and short-term investments$394M$448M$511M$72.1M$8.04M
Net receivables$4.87M$2.84M$1.06M$220K$150K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$421.7M$474.3M$514.2M$76.5M$9.64M
Property, plant and equipment, net$2.14M$3.64M$3.95M$330K$50K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$115M
Total non-current assets$2.74M$3.64M$12.4M$330K$50K
Total assets$424.4M$477.9M$526.5M$76.8M$9.68M
Accounts payable$0.00$8.68M$1.46M$50K$1.23M
Short-term debt$1.23M$1.37M$1.2M$150K$15M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$45.5M$22.5M$9.97M$7.67M$21.1M
Long-term debt$74.9M$1.46M$2.5M$130K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$74.5M$2.08M$3.08M$410K$240K
Capital lease obligations$370K$2.83M$3.7M$280K$0.00
Total liabilities$120M$24.5M$13.1M$8.08M$21.3M
Common stock$10K$10K$10K$10K$40K
Retained earnings-$-462.91M-$-235.59M-$-116.66M-$-80.65M-$-53.64M
Accumulated other comprehensive income (loss)$600K$5M$2.36M$350K-$-170K
Total equity$304.5M$453.4M$513.5M$68.8M-$-11.65M
Total investments$59.5M$267.6M$59.8M$32.6M$115M
Total debt$75.7M$2.83M$3.7M$280K$15M
Net debt-$-258.81M-$-177.6M-$-447.47M-$-39.22M$6.96M
Cash flow statement
20252024202320222021
Net income-$-229.1M-$-121.24M-$-44.08M-$-49.97M-$-53.64M
Depreciation and amortization$2.62M$1.38M$10K$10K$0.00
Stock-based compensation$12.9M$7.28M$7.11M$9.65M$10.9M
Change in working capital$19.9M-$-3.78M-$-6.22M-$-1.43M$4.48M
Accounts receivable-$-2.02M-$-1.79M-$-840K-$-70K-$-150K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00-$-1.31M$1.57M
Net cash provided by operating activities-$-196.01M-$-116.59M-$-42.78M-$-55.89M-$-35.18M
Investments in property, plant and equipment-$-40K-$-520K-$-280K-$-20K-$-50K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$203M-$-205.6M-$-25.18M-$-32.34M-$-50K
Common stock issued$73M$52.5M$482.5M$0.00$28.3M
Common stock repurchased$0.00-$0.00$0.00$0.00-$-10K
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$146M$51.3M$479.7M$119.7M$43.3M
Net change in cash$154.1M-$-270.74M$411.7M$31.5M$6.7M
Cash at end of period$334.5M$180.4M$451.2M$39.5M$8.04M
Operating cash flow-$-196.01M-$-116.59M-$-42.78M-$-55.89M-$-35.18M
Capital expenditure-$-40K-$-520K-$-280K-$-20K-$-50K
Free cash flow-$-196.04M-$-117.11M-$-43.06M-$-55.91M-$-35.23M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About MoonLake Immunotherapeutics

        MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.

        CEO
        Jorge Santos da Silva
        Employees
        130
        Beta
        1.04

        Explore

        Frequently asked questions

        What is the intrinsic value of MoonLake Immunotherapeutics (MLTX)?

        InvestorsCraft does not currently publish an intrinsic value for MLTX. How the IC value is calculated.

        Is MLTX undervalued?

        InvestorsCraft does not publish an undervaluation signal for MLTX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.